Am Fam Physician. 2009 Oct 1;80(7):668.
Original Article: The Visually Impaired Patient
Issue Date: May 15, 2008
Available at: http://www.aafp.org/afp/20080515/1431.html
to the editor: The article on the visually impaired patient by Drs. Rosenberg and Sperazza is an important review of eye disease for the family physician. However, the article contains some omissions.
The authors correctly state that visual acuity using a standard Snellen chart should be used to assess all patients for visual impairment. However, this test has to be performed under standard conditions so that inconsistency in acuity measurements does not lead to inappropriate clinical decision making. The two critical variables are the distance between the patient and the chart, and the illumination of the chart. The distance should be permanently marked so that it cannot be erased, and the patient should be placed directly behind that mark. The chart can be illuminated by directing a spotlight at it.1
The section of their article on age-related macular degeneration (ARMD) is not current. The authors state, “if neovascularization develops [in patients with nonexudative ARMD], retinal laser therapy has proved to be useful”; they add, “photodynamic therapy and intravitreal injections of antivascular endothelial growth factor and corticosteroids have shown promise in treating subsets of patients with macular degeneration.” Photodynamic therapy has been superseded by antivascular endothelial growth factor antibodies such as ranibizumab (Lucentis) and bevacizumab (Avastin), which have been shown to be superior in clinical trials; these are now the treatment of choice for exudative (“wet”) ARMD.2,3 Rapid referral to an ophthalmologist for intraocular injection of one of these agents is essential because undue delay could lead to irreversible loss of vision in the affected eye.
The authors state that “glaucoma causes increased ocular pressure that can damage the ganglion cell layer of the retina and cause visual loss.” Raised intraocular pressure is only one risk factor for the development of glaucoma, a condition that has a multifactorial etiology. Glaucoma is characterized by gradual progressive loss of the retinal ganglion cell nerve fiber layer that then manifests as visual field loss and may eventually cause total irreversible blindness in the affected eye.4
Author disclosure: Nothing to disclose.
REFERENCESshow all references
1. Pandit JC. Testing acuity of vision in general practice: reaching recommended standard. BMJ. 1994;309(6966):1408....
2. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18(6):502–508.
3. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol. 2007;144(4):627–637.
4. Quigley HA. New paradigms in the mechanisms and management of glaucoma. Eye. 2005;19(12):1241–1248.
editor's note: This letter was sent to the authors of “The Visually Impaired Patient,” who declined to reply.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: firstname.lastname@example.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2009 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions